APP下载

吉西他滨联合顺铂治疗远处转移性鼻咽癌的效果观察

2017-01-07王帆易军

中国当代医药 2016年30期
关键词:顺铂

王帆++++++易军

[摘要]目的 观察吉西他滨+顺铂(GP方案)治疗转移性鼻咽癌的近期效果及不良反应。方法 将2015年7月~2016年5月我院收治的46例远处转移性鼻咽癌患者随机分为观察组和对照组,各23例。其中观察组采用GP方案静脉点滴全身化疗,吉西他滨1000 mg/m2,d1、d8;顺铂25 mg/m2,d1~d3。对照组采用顺铂25 mg/m2,d1~d3;氟尿嘧啶0.75 mg/m2,d1~d5。21 d为1个周期,全部完成4个周期化疗。比较两组治疗效果和毒副作用发生情况。结果 观察组治疗客观有效率、疾病控制率均显著高于对照组(78.26% vs 43.48%;95.65% vs 69.56%)(P<0.05)。两组患者主要毒副作用为白细胞减少、血小板减少、贫血、恶心呕吐和转氨酶升高,两组各种毒副作用严重程度比较,差异无统计学意义(P>0.05)。结论 GP方案对转移性鼻咽癌有较好近期疗效,且毒副作用较轻,可作为转移性鼻咽癌的一线化疗。

[关键词]吉西他滨;顺铂;鼻咽癌;化学治疗

[中图分类号] R739.6 [文献标识码] A [文章编号] 1674-4721(2016)10(c)-0072-03

[Abstract]Objective To observe the short-term efficacy and adverse reaction of Gemcitabine plus Cisplatin(GP regimen) in the treatment of metastatic nasopharyngeal carcinoma (NPC).Methods 46 patients with metastatic NPC treated in our hospital from July 2015 to May 2016 were randomly divided into observation group and control group,23 cases in each group.In the observation group,GP regimen was used for intravenous drip chemotherapy,with Gemcitabine 1000 mg/m2,d1,d8;Cisplatin 25 mg/m2,d1-d3.Patients in the control group were given Cisplatin 25 mg/m2,d1-d3;FU 0.75 mg/m2, d1-d5.21 days for a cycle,the whole chemotherapy contained 4 cycles.The therapeutic effect and side effects of the patients were observed.Results The objective effective rate and disease control rate in the observation group was significantly higher than that in the control group(78.26% vs 43.48%;95.65% vs 69.56%) (P<0.05).The main side effects of two groups were white blood cell reduction,thrombocytopenia,anemia,nausea and vomiting,and elevated aminotransferase.The two groups had no significant difference in the severity of toxicity (P>0.05).Conclusion GP regimen has a good short-term effect on metastatic NPC,and the toxicity is mild,which can be used as first-line chemotherapy for metastatic NPC.

[Key words]Gemcitabine;Cisplatin;Nasopharyngeal carcinoma;Chemotherapy

鼻咽癌是我国最为常见的恶性肿瘤之一,尤其在我国南方发病率较高。病理诊断结果显示约90%为未分化或低分化的鳞状细胞癌,恶性程度较高,75%初诊患者已是Ⅲ~Ⅳ期[1]。目前鼻咽癌临床治疗方案以放射治疗为主,但对于已经发生远处器官转移的鼻咽癌患者,以全身化疗为主要治疗方案,常采用的化疗方案有氟尿嘧啶+顺铂(FP方案)、紫杉醇类+顺铂(TP方案)[2]。既往FP方案化疗器官转移性鼻咽癌有效率较低,缓解期较短。吉西他滨为细胞周期特异性抗代谢类药物,研究表明吉西他滨亦是临床常用的鼻咽癌化疗药物,毒副作用较低,但治疗失败率较高,可达48.1%[3]。有关文献显示吉西他滨与顺铂联合有协同作用[4]。本研究采用吉西他滨+顺铂(GP方案)治疗远处转移性鼻咽癌患者,现报道如下。

1资料与方法

登录APP查看全文

猜你喜欢

顺铂
多西他赛联合顺铂治疗晚期头颈部肿瘤的效果观察
培美曲塞联合顺铂与吉西他滨联合顺铂在非小细胞肺癌治疗中的应用分析
吉西他滨或长春瑞滨联合顺铂治疗晚期非小细胞肺癌的临床效果
细胞自噬与人卵巢癌细胞对顺铂耐药的关系
紫杉醇联合顺铂冶疗食管癌的效果观察
顺铂联合恩度胸腔内灌注治疗晚期非小细胞肺癌恶性胸腔积液的临床观察
顺铂联合恩度胸腔内灌注治疗晚期非小细胞肺癌恶性胸腔积液的临床观察
奈达铂与顺铂同步放化疗治疗中晚期宫颈癌的疗效差异
吉西他滨联合顺铂治疗晚期三阴乳腺癌的疗效观察